In what situations should patients with no history of thrombosis be tested for thrombophilia? Should the testing be performed in women planning hormonal contraception or menopausal hormone therapy?
Should homocysteine and MTHFR polymorphism testing be performed in patients with suspected thrombophilia?
In what situations should we perform additional testing for thrombophilia in patients without antiphospholipid syndrome and without any of the 5 basic congenital thrombophilias? What tests to order? Should they include the activity of coagulation factors VIII, IX, and X, and evaluation of the fibrinolytic system (TAFI, plasminogen, PAI-1 activity)?
If you were to name the 3 most important recent advances in hematology that are relevant for everyday practice, what would they be?
Dr Mark Crowther from McMaster University shares his views on the 3 most important recent advances in the management of nonmalignant blood diseases.
What is your management of secondary thrombocytosis?
Do you perform cytogenetic tests in every patient with a myeloproliferative neoplasm (MPN)?
Do you treat low-risk asymptomatic patients with primary myelofibrosis (PMF)?
How do you reduce the risk of infection in patients treated with ruxolitinib?
English
Polski
Español
українська